The Centers for Medicare & Medicaid Services yesterday approved Louisiana’s Medicaid plan amendment allowing supplemental rebate agreement negotiations with prescription drug makers for Hepatitis C therapies. The new “modified subscription” model allows the state to cap gross expenditures for the Hepatitis C prescriptions for Medicaid and requires manufacturers to provide the drug’s lowest price negotiated in all states in the Medicaid program. “The high cost of prescription drugs is one of the greatest challenges in our health care system,” said CMS Administrator Seema Verma, “and Louisiana’s innovative approach to leveraging a subscription model to promote access to hepatitis C therapy is a great example of how states can lead in designing solutions.” The amendment goes into effect July 1. CMS has approved similar state plan amendments for Washington, Oklahoma, Michigan and Colorado. This is the second one to focus on Hepatitis C.

Related News Articles

Headline
The House July 3 voted 218-214 to pass the final version of the One Big Beautiful Bill Act (H.R. 1), which enacts many of President Trump’s legislative…
Headline
The Senate narrowly passed the One Big Beautiful Bill Act (H.R. 1) on July 1 by a 50-50 tally, with Vice President J.D. Vance casting the tie-breaking vote.…
Headline
The AHA June 29 sent a letter to senators urging them to amend the budget reconciliation bill before its final passage in the Senate. The Senate version of the…
Headline
The latest video in the AHA’s series “Medicaid: Real Lives, Real Care” features Melissa Fannon-Wisner, DNP, nurse educator and nurse practitioner at Valley…
Headline
In a Q&A, Becky Pletzer, a social worker and mother, explains how critical Medicaid has been to support her son with disabilities, and why cuts to the…
Blog
Public
A Q&A with Becky Pletzer, social worker and parent to a son with disabilities Q: Can you tell me about yourself and your family?A: I’m Dr. Becky…